The Genetics Podcast

This week on The Genetics Podcast, Patrick is joined by Dr. Andrew Jackson, Programme Leader at the MRC Human Genetics Unit at the University of Edinburgh. They discuss how his lab discovered that gain-of-function DNMT3A mutations cause both microcephalic dwarfism and an accelerated aging syndrome, and what that reveals about the shared biology of growth and aging.
Show Notes
0:00 Intro to The Genetics Podcast
00:59 Welcome to Andrew
01:34 The origins of Andrew's work linking brain size and aging
02:54 The genetics of mammalian size range and epigenetic factors regulating growth
05:02 How DNMT3A mutations causing dwarfism led to discovering an accelerated aging syndrome
09:46 Cell number rather than cell size as the shared driver of growth and aging
13:07 Whether brain size within humans actually predicts cognitive ability
15:20 Why intellectual disability has far more known genes than dwarfism
19:26 Discovering ribonuclease H2's role in DNA repair, and its unexpected link to cancer 
23:35 Why studying rare monogenic diseases reveals broader biology
26:59 Andrew's next research questions on aging, cancer, and mutation biology
28:42 Why humans, model organisms, and cell assays each have a role
31:00 Somatic mosaicism's growing role in aging and disease beyond cancer
36:11 Closing remarks
Find out more:
Mentioned studies from Andrew’s lab: 
https://www.nature.com/articles/s41588-026-02633-8

https://www.nature.com/articles/s41588-018-0274-x

This week on The Genetics Podcast, Patrick is joined by Stevie Ringel, co-founder of Nome and founder of the Kizuna Foundation. They discuss Stevie's own ultra-rare disease diagnosis and shaped his path to founding Kizuna Foundation and Nome, how Nome's AI agents help scientists navigate the operational complexity of small-batch drug development, the technical and business model advantages underpinning Nome's accuracy, and what it will take to build a sustainable funding model for ultra-rare disease.
Show Notes
0:00 Intro to The Genetics Podcast
00:59 Welcome to Stevie
01:37 Stevie's inherited retinal disease (IRD) diagnosis and subsequent path into genomics
03:16 Why Stevie founded Kizuna Foundation and why ultra-rare drug development is so operationally complex
06:27 The origin story of Nome and using AI to automate the operational work 
10:09 The inspiration for the name “Nome” and who the company is built to serve
12:44 The biggest blockers to program speed
15:07 How AI and scale can bring down the cost of gene therapy manufacturing
18:01 FDA signals and global regulatory competition 
19:33 Priority review vouchers and why Nome stays out of molecule IP
20:33 Nome's AI and review process for patient reports and its expansion to health systems
25:04 Nome's agent architecture and the data behind its accuracy
28:17 Why delivery remains gene therapy's biggest bottleneck and approaches for solving it
31:34 The case for a new capital model in rare disease drug development 
33:25 What’s next for Nome as they advance preclinical programs
34:25 Nome’s focus on process excellence across therapeutic modalities
36:34 Closing remarks
Find out more: Nome

This week on The Genetics Podcast, Patrick is joined by Dr. Jagesh Shah, Chief Scientific Officer at Mirai Bio. They discuss why delivery is a central bottleneck holding back nucleic acid medicines, how Mirai's lipid nanoparticle (LNP) platform is built to reach tissues like adipocytes and T cells, and the machine learning feedback loop the company uses to engineer LNP formulations.
Show Notes
0:00 Intro to The Genetics Podcast
01:00 Welcome to Jagesh
01:40 Why delivery is the main bottleneck for gene therapies
03:42 Easier vs harder tissues to target for delivery
06:40 Overview of Mirai's modular delivery platform 
09:02 Comparing viral vectors and lipid nanoparticles (LNPs) 
12:18 Different approaches for targeting adipocytes and T cells with LNPs
15:49 Mirai's machine learning (ML) feedback loop for optimizing LNP formulation
20:50 Why lipid chemistry is still hard for ML to learn and factors affecting LNP tropism
24:35 Jagesh's path from academia to Mirai
27:23 Mirai's platform business model and how it lowers risk
29:13 What industry partnerships with Mirai look like
31:41 Mirai's next frontier of delivery to muscle tissue and the brain 
34:40 Cargo size and immunogenicity of LNPs vs AAV 
36:00 Why the field needs to close the regulatory pace gap 
37:19 Closing remarks
Find out more:
Mirai Bio

This week on The Genetics Podcast, Patrick is joined by Sharon Terry, President & CEO of Genetic Alliance. They discuss how Sharon established a layperson-led biobank, her long-term work on rare diseases and patient advocacy, and her program to bring genetic technology to patients in low- to middle-income countries. We’re re-running this episode for its enduring lessons on patient advocacy, rare disease parenting, communication, and citizen science. 

Show Notes
0:00 Intro to The Genetics Podcast
00:59 Welcome to Sharon and a discussion of the personal experience with rare disease that started her journey
03:47 Reasons Sharon decided to establish the first layperson-led biobank
05:34 Challenges with setting up the biobank infrastructure
07:00 Balancing financial factors in a non-profit organization 
09:30 Recent patterns and future insight into rare disease drug discovery framework and regulation
15:32 Barriers to widespread collaboration and cooperation in rare disease research, and why it should be approached from a public health perspective
18:12 Background and experiences from the iHope Genetic Health program in low- to middle-income countries
24:44 Sharon’s perspective on challenges with the Genetic Information Non-discrimination Act
28:49 Sharon’s lessons learned in her patient advocacy and policy work, and her hopes for future legislation
33:04 Sharon’s hopes for improved access to genetic testing and treatment for children in underserved communities
34:34 How Sharon learned about rare diseases and genetics as a “homeschooling mom without a degree”
37:54 Insights into how elements of spirituality can support advocacy work
40:18 Closing remarks

This week on The Genetics Podcast, Patrick is joined by Dr. Carl Anderson, Senior Group Leader and Head of the Human Genetics Programme at the Wellcome Sanger Institute, where he leads the Genomics of Inflammation and Immunity Group. They discuss IBDVerse, the single-cell atlas Carl's team built to map genetic effects on gene regulation across gut cell types, how coding and non-coding variants converge on shared biological pathways in inflammatory bowel disease, and Carl's vision for longitudinal multi-omics cohorts built around the sickest and most underrepresented hospital patients.
Show Notes
0:00 Intro to The Genetics Podcast
00:58 Welcome to Carl
02:05 The origins of IBDVerse and mapping genetic effects on gene regulation across gut cell types in IBD
05:43 How anti-TNFs and newer genetically-supported IBD drugs have reshaped treatment 
08:04 Genetic versus environmental contributions to IBD
09:53 Using single-cell data to uncover IBD disease subtypes
13:22 Drug sequencing and immunogenicity in treatment response
16:52 The backstory of building the IBDVerse atlas at scale
20:29 How coding and non-coding IBD variants converge on the same genes and pathways
23:38 The case for pathway-specific polygenic risk scores
28:17 Building a longitudinal multi-omics dataset to predict IBD progression and drug response
30:08 Why Sanger's next cohort targets sick and underrepresented patients rather than healthy volunteers
34:07 What Carl looks for when interviewing PhD students and faculty candidates 
39:20 A call to junior scientists and closing remarks
Find out more:
IBDverse study